We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$696M
AUM Growth
+$65M
Cap. Flow
+$38.4M
Cap. Flow %
5.52%
Top 10 Hldgs %
28.66%
Holding
112
New
8
Increased
33
Reduced
36
Closed
4

Top Buys

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$15.7M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$12M
3
EXEL icon
Exelixis
EXEL
+$8.89M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.34M
5
SNY icon
Sanofi
SNY
+$7.65M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$10.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.58M
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$7.12M
4
ESPR
Esperion Therapeutics
ESPR
+$6.62M
5
BIIB icon
Biogen
BIIB
+$5.16M

Sector Composition

Rank Sector Weight
1 Healthcare 92.59%
2 Financials 0.93%
3 Technology 0.13%
4 Energy 0.1%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$28.8M 4.13%
2,422,090
+670,768
+38% +$8.34M
EXEL icon
2
Exelixis
EXEL
$13.3B
$25.9M 3.71%
1,050,000
+420,000
+67% +$8.89M
NVCR icon
3
NovoCure
NVCR
$1.73B
$21M 3.02%
+1,216,314
New +$15.7M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$18.7M 2.69%
154,000
+42,298
+38% +$4.92M
CELG
5
DELISTED
Celgene Corp
CELG
$18.4M 2.65%
142,000
+49,000
+53% +$6M
GILD icon
6
Gilead Sciences
GILD
$162B
$18.2M 2.61%
256,916
+50,000
+24% +$3.33M
INCY icon
7
Incyte
INCY
$24.2B
$17.6M 2.53%
140,046
+25,046
+22% +$3.19M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.6B
$17.2M 2.47%
189,300
+64,300
+51% +$5.85M
MDT icon
9
Medtronic
MDT
$109B
$17M 2.44%
191,115
+10,000
+6% +$843K
ESPR
10
DELISTED
Esperion Therapeutics
ESPR
$16.8M 2.41%
363,347
-180,000
-33% -$6.62M
UNH icon
11
UnitedHealth
UNH
$376B
$16.7M 2.4%
90,000
+25,000
+38% +$4.38M
NKTR icon
12
Nektar Therapeutics
NKTR
$2.39B
$15.5M 2.23%
53,000
+21,667
+69% +$6.26M
ABMD
13
DELISTED
Abiomed Inc
ABMD
$15.2M 2.18%
106,150
-10,898
-9% -$1.46M
PFE icon
14
Pfizer
PFE
$143B
$14.5M 2.08%
453,665
+100,130
+28% +$3.16M
GKOS icon
15
Glaukos
GKOS
$9.83B
$14.3M 2.06%
345,450
+19,650
+6% +$846K
NDRM
16
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$13.8M 1.98%
+461,654
New +$12M
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$15.9B
$13.2M 1.9%
85,020
+24,700
+41% +$3.78M
BIIB icon
18
Biogen
BIIB
$30B
$13.2M 1.89%
48,500
-19,500
-29% -$5.16M
AGN
19
DELISTED
Allergan plc
AGN
$12.6M 1.82%
52,000
-7,000
-12% -$1.64M
LLY icon
20
Eli Lilly
LLY
$1.02T
$12.3M 1.77%
150,000
-20,000
-12% -$1.63M
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$121B
$12.2M 1.76%
95,013
– –
ZBH icon
22
Zimmer Biomet
ZBH
$18.2B
$11.6M 1.66%
92,700
+20,600
+29% +$2.44M
NVRO
23
DELISTED
NEVRO CORP.
NVRO
$11.5M 1.66%
155,118
+42,504
+38% +$3.41M
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$10.3M 1.49%
833,154
+117,490
+16% +$1.36M
ESRX
25
DELISTED
Express Scripts Holding Company
ESRX
$9.96M 1.43%
156,000
+60,000
+63% +$3.77M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rhenman & Partners Asset Management held 112 positions worth $696M, up 10% from $631M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $38.4M of net new capital in Q2 2017, opening 8 new positions and adding to 33 existing holdings. Its largest new stake was NovoCure: 1,216,314 shares worth $21M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amgen, an estimated $10.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2017 buy was NovoCure: 1,216,314 shares worth $21M.
  • Rhenman & Partners Asset Management added most to Exelixis in Q2 2017, an estimated $8.89M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2017 reduction was Amgen, cutting an estimated $10.6M.
  • Rhenman & Partners Asset Management fully exited Viatris in Q2 2017, selling an estimated $3.51M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $696M portfolio in Q2 2017.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q2 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 10% quarter-over-quarter to $696M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2017, filed 11 Jul 2017.